Urologic Diseases  >>  ciprofloxacin (Q3939)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ciprofloxacin (Q3939) / Bayer, Novartis
EXPRESS, NCT00663806: A Phase IV Study of Cipro XR in Uncomplicated UTI

Completed
4
7614
US
Cipro XR (Ciprofloxacin, BAYQ3939)
Bayer
Urinary Tract Infections
 
07/03
NCT00676533: Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections

Completed
4
276
US
Cipro XR (Ciprofloxacin, BAYQ3939)
Bayer
Urinary Tract Infection
 
01/04
NCT00481689: Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens

Completed
4
500
US
Cipro XR (Ciprofloxacin, BAYQ3939)
Bayer
Urinary Tract Infections
 
09/05

Download Options